Biotechnology

Dyne Therapeutics

Dyne Therapeutics released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7322 (forecast USD -0.7716)

Dyne Therapeutics Discusses 2026 Commercial Transformation and Neuromuscular Disease Projects

Dyne Therapeutics released FY2025 Q4 earnings on March 2, 2026 (EST), with actual EPS of USD -0.7584 (forecasted USD -0.7758)

Dyne Therapeutics released FY2025 earnings on March 2, 2026 (EST), actual EPS USD -3.474 (forecast USD -3.5069)

Stifel Nicolaus analyst maintains buy rating on Dyne Therapeutics

TFG Asset Management GP Acquired Dyne Therapeutics Inc. Stock in Q2

Dyne Therapeutics Completes IPO Raising $402.5 Million

Dyne Therapeutics Offering 18.98 Million New Shares

Chardan Capital Reiterates Buy Rating for Dyne Therapeutics

Dyne Therapeutics Launches $300 Million Common Stock Firm Offering

Dyne Therapeutics Inc. amends loan agreement to receive $50 million loan

Morgan Stanley Raises Price Target and Maintains Overweight Rating for Dyne

Dyne Therapeutics reports positive results for z-rostudirsen in Duchenne Muscular Dystrophy Phase 1/2 clinical trial

Dyne Therapeutics Chief Medical Officer Douglas Kerr Sold Company Common Stock

Oppenheimer Downgrades Dyne Therapeutics Target Price

Oppenheimer analyst maintains hold rating on Dyne Therapeutics

Analysts Maintain Buy Rating for Dyne Therapeutics, Price Targets Set at $36 and $48

Dyne Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7618 (forecast USD -0.8383)

Dyne Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST), with actual revenue of USD 0 and actual EPS of USD -2.7849

Dyne Therapeutics Reports Positive Clinical Data and Future Plans for DMD and DM1 Therapies

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SBIO

ARKG

LABU

Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics for approximately $14.17 million, reducing its stake to 966,609 shares valued at $17.52 million. Despite this sale, Dyne's stock has risen nearly 40% over the past year, outperforming the S&P 500. The company is focused on developing therapeutics for rare muscle diseases and has a strong cash position of $972.2 million, funding operations into 2028. Investors are advised to consider other stocks as Dyne was not included in a recent top 10 list by The Motley Fool.

nasdaq

iShares Biotechnology ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Alumis

Amylyx Pharmaceuticals

Abivax SA

Vaxcyte

Pharvaris BV

S&P 500

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Dyne Therapeutics (DYN) has experienced a recent pullback, closing at $17.29, with a mixed performance over various time frames. Despite a 15.3% decline in the past month, it shows an 11.3% return over three months and a 46.2% return over the year. The company trades at a P/B of 3.3x, above the industry average, indicating a premium valuation. However, it faces risks, including a significant net loss of $451.707 million. A DCF analysis suggests a potential future value of $105.60, raising questions about current pricing.

Simplywall

Assessing Dyne Therapeutics (DYN) Valuation After Recent Pullback And Contrasting P/B And DCF Signals

LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of $44.00. Brisebois, a 3-star analyst, has an average return of 2.4% and a 40.11% success rate. Dyne Therapeutics also received a Buy rating from Evercore ISI, while Bernstein assigned a Hold rating on May 13.

Tip Ranks

Savara

Praxis Precision Medicines

Opus Genetics

Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital

Wall Street Zen upgraded Dyne Therapeutics (NASDAQ:DYN) from a 'strong sell' to a 'sell' rating. Other analysts have varied opinions, with Weiss Ratings maintaining a 'sell' and Chardan Capital issuing a 'buy' with a $38 price target. Dyne's stock opened at $17.29, with a market cap of $2.86 billion. The company reported earnings of ($0.73) per share, beating estimates. Insider trading saw significant share sales, and institutional investors hold 96.68% of the stock.

Market Beat

Jefferies Financial

JPMorgan Chase

Goldman Sachs

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

GS Hldg R

Dyne Therapeutics (NASDAQ:DYN) Upgraded at Wall Street Zen

Dyne Therapeutics CEO John Cox sold 3,311 shares at $18.36 each, totaling $60,789.96, to cover tax obligations from equity awards. Post-sale, he holds 370,834 shares valued at approximately $6.8 million, marking a 0.88% decrease in ownership. The stock is currently trading at $18.28, with a market cap of $3.02 billion. Analysts have mixed ratings on DYN, with a consensus of "Moderate Buy" and an average target price of $35.21. Recent estimates for EPS have been raised by some analysts, while others have cut long-term forecasts.

T. Rowe Price

Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares

HC Wainwright has raised its Q2 2026 EPS estimate for Dyne Therapeutics (NASDAQ:DYN) from ($0.76) to ($0.68) per share, maintaining a "Buy" rating with a $50.00 price target. The consensus estimate for the company's full-year earnings is ($2.97) per share. Dyne's stock opened at $18.44, with a market cap of $3.05 billion. Institutional investors hold 96.68% of the stock, and recent insider trading saw Director Jason P. Rhodes sell 83,219 shares. Overall, Dyne Therapeutics has a consensus rating of "Moderate Buy" with an average target price of $35.21.

Morgan Stanley

Bank of NY Mellon

Fifth Third Bancorp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

Fifth Third Bancorp Pref Share FITBO 4.95 Perp 09/30/24 K

FIFTH THIRD BANK PREF SHARE FITB V6.625 P12/31/49 I

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

Fifth Third Bancorp Depositary Shs B Ser A Repr 1/40 6 % Perp Pfd Registered Shs B Ser A

HC Wainwright Has Optimistic Outlook of DYN Q2 Earnings

In Waltham, Massachusetts, on May 13, 2026, Dyne Therapeutics, Inc. (Nasdaq: DYN), which specializes in developing treatments for individuals with genetically driven neuromuscular disorders, revealed plans for their involvement in upcoming investor conferences.

Unusual Whales

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings, reporting an EPS of ($0.73), surpassing estimates of ($0.74). This is an improvement from the previous year's EPS of ($1.05). The stock rose to $18.22, with a market cap of $3.01 billion. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $35.14. Insiders have sold significant shares recently, and institutional investors hold 96.68% of the stock. Dyne focuses on gene regulation therapies for rare diseases, including Duchenne muscular dystrophy.

VG Health

Health Care Select Sector SPDR

Dyne Therapeutics (NASDAQ:DYN) Announces Earnings Results

Dyne Therapeutics(DYN.US)